Total Liabilities Summary of Evotec SE

Evotec SE's latest annual total liabilities in 2023 was 1.17 Billion EUR , up 10.19% from previous year.
Evotec SE's latest quarterly total liabilities in 2024 Q2 was 987.42 Million EUR , down -10.41% from previous quarter.
Evotec SE reported annual total liabilities of 1.07 Billion EUR in 2022, up 24.79% from previous year.
Evotec SE reported annual total liabilities of 857.47 Million EUR in 2021, up 15.87% from previous year.
Evotec SE reported quarterly total liabilities of 987.42 Million EUR for 2024 Q2, down -10.41% from previous quarter.
Evotec SE reported quarterly total liabilities of - EUR for 2023 Q1, down -100.0% from previous quarter.

Annual Total Liabilities Chart of Evotec SE (2023 - 2001)

Historical Annual Total Liabilities of Evotec SE (2023 - 2001)

Year	Total Liabilities	Total Liabilities Growth
2023	1.17 Billion EUR	10.19%
2022	1.07 Billion EUR	24.79%
2021	857.47 Million EUR	15.87%
2020	740.04 Million EUR	5.14%
2019	703.88 Million EUR	102.85%
2018	347 Million EUR	3.42%
2017	335.52 Million EUR	144.14%
2016	137.43 Million EUR	35.47%
2015	101.44 Million EUR	53.2%
2014	66.21 Million EUR	-3.21%
2013	68.41 Million EUR	-6.13%
2012	72.88 Million EUR	2.69%
2011	70.96 Million EUR	19.83%
2010	59.22 Million EUR	68.67%
2009	35.11 Million EUR	6.27%
2008	33.04 Million EUR	-11.48%
2007	37.32 Million EUR	-45.39%
2006	68.35 Million EUR	82.55%
2005	37.44 Million EUR	307.75%
2004	9.18 Million EUR	61.18%
2003	5.69 Million EUR	0.0%
2002	- EUR	0.0%
2001	- EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	1.1 Billion EUR	-6.53%
2024 Q2	987.42 Million EUR	-10.41%
2023 Q1	- EUR	-100.0%
2023 Q4	1.17 Billion EUR	5.88%
2023 Q3	1.11 Billion EUR	-1.18%
2023 Q2	1.12 Billion EUR	0.0%
2023 FY	1.17 Billion EUR	10.19%
2022 FY	1.07 Billion EUR	24.79%
2022 Q1	875.16 Million EUR	2.06%
2022 Q3	1.03 Billion EUR	1.57%
2022 Q4	1.07 Billion EUR	3.47%
2022 Q2	1.01 Billion EUR	16.34%
2021 Q3	775.17 Million EUR	0.86%
2021 Q1	787.66 Million EUR	6.43%
2021 FY	857.47 Million EUR	15.87%
2021 Q2	768.54 Million EUR	-2.43%
2021 Q4	857.47 Million EUR	10.62%
2020 Q3	696.89 Million EUR	-2.48%
2020 FY	740.04 Million EUR	5.14%
2020 Q1	694.09 Million EUR	-1.39%
2020 Q2	714.59 Million EUR	2.95%
2020 Q4	740.04 Million EUR	6.19%
2019 Q3	621.29 Million EUR	-1.14%
2019 Q2	628.47 Million EUR	45.29%
2019 FY	703.88 Million EUR	102.85%
2019 Q4	703.88 Million EUR	13.29%
2019 Q1	432.56 Million EUR	24.66%
2018 FY	347 Million EUR	3.42%
2018 Q2	340.7 Million EUR	4.51%
2018 Q3	380.08 Million EUR	11.56%
2018 Q1	326.01 Million EUR	-2.83%
2018 Q4	347 Million EUR	-8.7%
2017 Q3	325.72 Million EUR	203.65%
2017 FY	335.52 Million EUR	144.14%
2017 Q1	105.41 Million EUR	-23.29%
2017 Q2	107.27 Million EUR	1.76%
2017 Q4	335.52 Million EUR	3.01%
2016 FY	137.43 Million EUR	35.47%
2016 Q4	137.43 Million EUR	66.89%
2016 Q3	82.35 Million EUR	-3.57%
2016 Q2	85.39 Million EUR	-7.47%
2016 Q1	92.28 Million EUR	-9.03%
2015 Q1	64.67 Million EUR	-2.34%
2015 FY	101.44 Million EUR	53.2%
2015 Q3	107.1 Million EUR	-2.74%
2015 Q4	101.44 Million EUR	-5.29%
2015 Q2	110.12 Million EUR	70.29%
2014 Q3	58.02 Million EUR	-8.91%
2014 Q4	66.21 Million EUR	14.11%
2014 FY	66.21 Million EUR	-3.21%
2014 Q1	63.66 Million EUR	-6.94%
2014 Q2	63.7 Million EUR	0.07%
2013 Q1	72.52 Million EUR	-0.49%
2013 Q3	68.18 Million EUR	-2.43%
2013 Q2	69.88 Million EUR	-3.64%
2013 FY	68.41 Million EUR	-6.13%
2013 Q4	68.41 Million EUR	0.33%
2012 FY	72.88 Million EUR	2.69%
2012 Q2	64.37 Million EUR	-6.75%
2012 Q4	72.88 Million EUR	5.4%
2012 Q1	69.02 Million EUR	-2.73%
2012 Q3	69.14 Million EUR	7.42%
2011 Q1	56.46 Million EUR	-4.65%
2011 Q3	63.71 Million EUR	2.69%
2011 Q4	70.96 Million EUR	11.39%
2011 FY	70.96 Million EUR	19.83%
2011 Q2	62.04 Million EUR	9.87%
2010 Q4	59.22 Million EUR	29.72%
2010 FY	59.22 Million EUR	68.67%
2010 Q3	45.65 Million EUR	42.2%
2010 Q2	32.1 Million EUR	2.51%
2010 Q1	31.32 Million EUR	-10.8%
2009 Q3	33.29 Million EUR	-1.34%
2009 Q2	33.74 Million EUR	-14.43%
2009 Q1	39.44 Million EUR	19.37%
2009 FY	35.11 Million EUR	6.27%
2009 Q4	35.11 Million EUR	5.45%
2008 FY	33.04 Million EUR	-11.48%
2008 Q2	34.45 Million EUR	0.0%
2008 Q4	33.04 Million EUR	7.34%
2008 Q3	30.78 Million EUR	-10.66%
2007 Q3	36.97 Million EUR	0.0%
2007 FY	37.32 Million EUR	-45.39%
2007 Q4	36.36 Million EUR	-1.64%
2006 Q1	11.88 Million EUR	-3.25%
2006 Q3	11.76 Million EUR	5.67%
2006 Q4	71.17 Million EUR	505.18%
2006 FY	68.35 Million EUR	82.55%
2006 Q2	11.12 Million EUR	-6.36%
2005 Q1	8.43 Million EUR	-8.18%
2005 Q4	12.28 Million EUR	0.0%
2005 FY	37.44 Million EUR	307.75%
2005 Q2	8.23 Million EUR	-2.33%
2004 Q4	9.18 Million EUR	0.0%
2004 FY	9.18 Million EUR	61.18%
2004 Q2	8.15 Million EUR	0.53%
2004 Q1	8.1 Million EUR	42.31%
2003 Q4	5.69 Million EUR	0.0%
2003 FY	5.69 Million EUR	0.0%
2002 FY	- EUR	0.0%
2001 FY	- EUR	0.0%

Peer Total Liabilities Comparison of Evotec SE

Name	Total Liabilities	Total Liabilities Difference
MPH Health Care AG	15.38 Million EUR	-7563.511%
Apontis Pharma AG	27.2 Million EUR	-4235.092%
Dermapharm Holding SE	1.62 Billion EUR	27.516%
MERCK Kommanditgesellschaft auf Aktien	22.36 Billion EUR	94.728%
PharmaSGP Holding SE	91.54 Million EUR	-1188.05%
SynBiotic SE	19.59 Million EUR	-5918.82%

Global Stocks Search

Evotec SE (EVT.DE)

Total Liabilities Summary of Evotec SE

Annual Total Liabilities Chart of Evotec SE (2023 - 2001)

Historical Annual Total Liabilities of Evotec SE (2023 - 2001)

Peer Total Liabilities Comparison of Evotec SE